ReviewLiver international : official journal of the International Association for the Study of the Liver2026
Induction of Clinical Operational Tolerance Through Immunosuppression Minimization: Less Is More?
Review in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Induction of Clinical Operational Tolerance Through Immunosuppression Minimization: Less Is More?Liver international : official journal of the International Association for the Study of the Liver · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The goal of achieving clinical operational tolerance in liver transplantation has sparked significant interest, driven by the desire to mitigate the long-term adverse effects of immunosuppression. Advances in understanding the immunological mechanisms underpinning operational tolerance in liver transplantation have highlighted the central role of regulatory T cells and tolerogenic dendritic cells. These cells actively suppress effector immune responses and aid in achieving operational tolerance. Immunosuppressive medication differentially influences the expansion, survival, and function of these cells, demonstrating the importance of understanding the potential of immunosuppressive regimens to optimize the possibility of achieving an immunosuppression-free state. The potential of stepwise immunosuppressive reduction to achieve operational tolerance without compromising graft function has been demonstrated. The immunosuppressive withdrawal protocols underline the feasibility and safety of immunosuppressive withdrawal in selected liver transplant recipients, highlighting factors such as time since transplantation, recipient age, and gender as strong predictors of success. Furthermore, minimization of immunosuppressive, even early post transplantation, has been shown to be successful and sets the stage for successful immunosuppression withdrawal later. This review highlights the necessity to optimize immunosuppressive regimens by demonstrating its possibility to aid in achieving minimal immunosuppressive to maximize success rates of drug withdrawal and diminish the cumulative immunosuppressive related complications to increase the quality of life of liver transplant recipients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.